Pro RFID in BizTalk Server 2009

por Beckner, Mark, Simms, M, Ventatesh, R
Publicado 2009

Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer

por Simms, M S, Scholfield, D P, Jacobs, E, Michaeli, D, Broome, P, Humphreys, J E, Bishop, M C
Publicado 2000

Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cells

por Hirst, A M, Simms, M S, Mann, V M, Maitland, N J, O'Connell, D, Frame, F M
Publicado 2015

Induction of Germinal Centers by MMTV Encoded Superantigen on B Cells

por Simmons, W. J., Simms, M., Chiarle, R., Mackay, F., Tsiagbe, V. K., Browning, J., Inghirami, G., Thorbecke, G. J.
Publicado 2001

Retinoic acid represses invasion and stem cell phenotype by induction of the metastasis suppressors RARRES1 and LXN

por Oldridge, E E, Walker, H F, Stower, M J, Simms, M S, Mann, V M, Collins, A T, Pellacani, D, Maitland, N J
Publicado 2013

HDAC inhibitor confers radiosensitivity to prostate stem-like cells

por Frame, F M, Pellacani, D, Collins, A T, Simms, M S, Mann, V M, Jones, GDD, Meuth, M, Bristow, R G, Maitland, N J
Publicado 2013

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

por Sydes, M R, Spears, M R, Mason, M D, Clarke, N W, Dearnaley, D P, de Bono, J S, Attard, G, Chowdhury, S, Cross, W, Gillessen, S, Malik, Z I, Jones, R, Parker, C C, Ritchie, A W S, Russell, J M, Millman, R, Matheson, D, Amos, C, Gilson, C, Birtle, A, Brock, S, Capaldi, L, Chakraborti, P, Choudhury, A, Evans, L, Ford, D, Gale, J, Gibbs, S, Gilbert, D C, Hughes, R, McLaren, D, Lester, J F, Nikapota, A, O’Sullivan, J, Parikh, O, Peedell, C, Protheroe, A, Rudman, S M, Shaffer, R, Sheehan, D, Simms, M, Srihari, N, Strebel, R, Sundar, S, Tolan, S, Tsang, D, Varughese, M, Wagstaff, J, Parmar, M K B, James, N D
Publicado 2018

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

por Clarke, N W, Ali, A, Ingleby, F C, Hoyle, A, Amos, C L, Attard, G, Brawley, C D, Calvert, J, Chowdhury, S, Cook, A, Cross, W, Dearnaley, D P, Douis, H, Gilbert, D, Gillessen, S, Jones, R J, Langley, R E, MacNair, A, Malik, Z, Mason, M D, Matheson, D, Millman, R, Parker, C C, Ritchie, A W S, Rush, H, Russell, J M, Brown, J, Beesley, S, Birtle, A, Capaldi, L, Gale, J, Gibbs, S, Lydon, A, Nikapota, A, Omlin, A, O'Sullivan, J M, Parikh, O, Protheroe, A, Rudman, S, Srihari, N N, Simms, M, Tanguay, J S, Tolan, S, Wagstaff, J, Wallace, J, Wylie, J, Zarkar, A, Sydes, M R, Parmar, M K B, James, N D
Publicado 2019

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: A...

por Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Amos, C.L., Attard, G., Brawley, C.D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D.P., Douis, H., Gilbert, D., Gillessen, S., Jones, R.J., Langley, R.E., MacNair, A., Malik, Z., Mason, M.D., Matheson, D., Millman, R., Parker, C.C., Ritchie, A.W.S., Rush, H., Russell, J.M., Brown, J., Beesley, S., Birtle, A., Capaldi, L., Gale, J., Gibbs, S., Lydon, A., Nikapota, A., Omlin, A., O’Sullivan, J.M., Parikh, O., Protheroe, A., Rudman, S., Srihari, N.N., Simms, M., Tanguay, J.S., Tolan, S., Wagstaff, J., Wallace, J., Wylie, J., Zarkar, A., Sydes, M.R., Parmar, M.K.B., James, N.D.
Publicado 2020